权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Understanding the role of TDP-43 in Alzheimer's disease and FTLD

了解 TDP-43 在阿尔茨海默病和 FTLD 中的作用

基本信息

批准号：
9132162
负责人：
Keith A Josephs
金额：
$ 32.49万
依托单位：
MAYO CLINIC ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-07-01 至 2020-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9132162
关键词：
Accounting Affect Alzheimer&apos s Disease Amyloid beta-Protein Atrophic Attention Autopsy Brain Cessation of life Characteristics Clinic Clinical Clinical Data Cognition DNA-Binding Proteins Deposition Frequencies Goals Guidelines Health Hippocampus (Brain)Image Immunohistochemistry Impaired cognition International Lewy Bodies MRI Scans Measures Memory Memory Loss Minnesota Modeling Molecular Target N-terminal Neocortex Nerve Degeneration Neurofibrillary Tangles Outcome Pathology Play Probability Process Proteins Public Health Recruitment Activity Role Scheme Staging Statistical Models Vascular Diseases Work abstracting base cerebral atrophy cognitive performance cohort gray matter hippocampal atrophy hippocampal sclerosis illness length improved link protein morphometry neocortical neuroimaging neuropsychological protein TDP-43 response tau Proteins therapeutic target

项目摘要

DESCRIPTION (provided by applicant): In the first cycle of our R01 we demonstrated that the transactive response DNA binding protein of 43 kDa (TDP-43) influences memory loss and hippocampal atrophy in Alzheimer's disease (AD). This showed that TDP-43 plays a key role in neurodegeneration in AD and represents an important new treatment target for AD. This work, however, was limited to subjects with advanced neuropathological stages of AD. If treating AD is going to be successful, there needs to be advancement in our understanding of how TDP-43 interacts with the other AD associated proteins of tau and beta-amyloid (Aß) to affect neurodegeneration across the entire spectrum of AD neuropathologic changes. The primary goal of our second cycle is therefore to determine how TDP-43, tau and Aß interact to account for neurodegeneration across all levels of AD neuropathologic changes. We aim to investigate the relationship between the frequency, burden and topographic distribution of TDP-43 and the topographic distributions of tau and Aß, and assess how these three proteins interact and influence clinical, neuropsychological and neuroimaging outcomes. We also aim to investigate whether neurodegeneration in AD is dependent on the ratio of C to N terminal TDP-43 specie, or TDP-43 subtype (A- D). To accomplish our aims we will perform pathological analyses on a cohort of 768 cases that have been prospectively recruited and autopsied between 1/1/2000 and 12/31/2013 at Mayo Clinic, Rochester, Minnesota. All 768 cases have already undergone a standard neuropathological assessment and been assigned a Braak neurofibrillary tangle stage measuring the distribution of tau deposition. For the renewal, we will perform Thal staging to assess Aß distribution on all 768 cases. TDP-43 immunohistochemistry was already performed on 342 cases in the first cycle, and so for this cycle we will perform TDP-43 immunohistochemistry on the remaining 426 cases to assess for 1) the presence of TDP-43, 2) TDP-43 distribution and assign each case a TDP-43 in AD stage, 3) TDP-43 burden in the hippocampus, 4) TDP-43 specie and 5) TDP-43 subtype. Clinical data will be abstracted for each case and tensor-based morphometry will be utilized to calculate volumes of the hippocampus and neocortex on all available MRI scans for each case. Statistical models will be utilized to assess the relationships between TDP-43, tau and Aß, accounting for other potentially confounding pathologies such as Lewy bodies, vascular disease and hippocampal sclerosis, and their relationship to cognitive impairment and brain atrophy across the AD neuropathologic spectrum. Ultimately, we aim to generate a model demonstrating how TDP-43, tau and Aß influence hippocampal and neocortical atrophy with disease duration. Findings from this R01 will significantly improve understanding of how these three potential molecular targets interact to influence the AD neurodegenerative process. Given that these proteins currently have the greatest potential as therapeutic targets for the treatment of AD, our R01 has potential for significant public health impact.